Biomarkers in atopic dermatitis and psoriasis


Start Date
End Date
IMI2 - Call 13
Grant agreement number

Type of Action: 
RIA (Research and Innovation Action)

IMI Funding
10 500 000
EFPIA in kind
10 384 847
Total Cost
20 884 847


Atopic dermatitis and psoriasis are serious skin diseases that affect over 300 million people globally. Atopic dermatitis causes itchy, inflamed skin that can become blistered, while psoriasis is characterised by red, scaly plaques on the skin. For many patients, the treatments available do not work well and the diseases place a huge burden on patients, their families, and healthcare systems. BIOMAP aims to shed new light on the underlying causes of both diseases, as well as the genetic and environmental factors that influence how a patient’s disease will progress and how well they will respond to a given treatment. They will do this by studying in depth data and samples from 50 000 patients as well as healthy individuals. Ultimately, BIOMAP hopes to identify new sub-types of the diseases that will allow clinicians and patients to make better, more personalised decisions on treatments. To ensure patients’ views are integrated into the project, BIOMAP has set up a Patient Advisory Group.

Participants Show participants on map

EFPIA companies
  • Boehringer Ingelheim Internationalgmbh, Ingelheim, Germany
  • Leo Pharma As, Ballerup, Denmark
  • Pfizer Limited, Sandwich, Kent , United Kingdom
  • Sanofi-Aventis Deutschland GMBH, Frankfurt / Main, Germany
  • UCB Biopharma SRL, Brussels, Belgium
Universities, research organisations, public bodies, non-profit groups
  • Academisch Medisch Centrum Bij De Universiteit Van Amsterdam, Amsterdam, Netherlands
  • Academisch Ziekenhuis Leiden, Leiden, Netherlands
  • Ait Austrian Institute Of Technology GMBH, Wien, Austria
  • Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
  • Christian-Albrechts-Universitaet Zu Kiel, Kiel, Germany
  • Den Selvejende Institution Dansk Borneastma Center, Gentofte, Denmark
  • Heinrich-Heine-Universitaet Duesseldorf, Düsseldorf, Germany
  • Itä-Suomen yliopisto, Kuopio, Finland
  • Karolinska Institutet, Stockholm, Sweden
  • King'S College London, London, United Kingdom
  • Klinikum Rechts Der Isar Der Technischen Universitat Munchen, Muenchen, Germany
  • Kobenhavns Universitet, Copenhagen, Denmark
  • London School Of Hygiene And Tropical Medicine Royal Charter, London, United Kingdom
  • Stichting Katholieke Universiteit, Nijmegen, Netherlands
  • Tampereen Korkeakoulusaatio Sr, Tampere, Finland
  • Tartu Ulikool, Tartu, Estonia
  • Technische Universitaet Muenchen, Muenchen, Germany
  • Trinity College Dublin, Dublin, Ireland
  • Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany
  • Universitat Wien, Vienna, Austria
  • Universite Du Luxembourg, Esch-sur-Alzette, Luxembourg
  • University Of Bristol, Bristol, United Kingdom
  • University Of Dundee, Dundee, United Kingdom
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Eurice European Research And Project Office GMBH, Saarbrücken, Germany
  • Information Technology For Translational Medicine (Ittm) SA, Esch-sur-Alzette, Luxembourg
Project coordinator
Stephan Weidinger
Christian-Albrechts-Universitaet Zu Kiel